10.15 Assignment Agreement, dated February 1, 2018, by and between the Company and NantOmics, LLC. 10-Q/A 001-37792 10.1 July 11, 2018 10.16 Promissory note dated August 8, 2018, by the Company to the benefit of Nant Capital, LLC. 10-Q 001-37792 10.1 August 9, 2018 10.17# Amended and Restated Consulting Agreement dated September 12, 2018, between the Company and Mr. Bob Petrou 10-Q 001-37792 10.2 November 21, 2018 10.18*** Asset Purchase Agreement dated as of January 13, 2020, among Masimo Corporation and VCCB Holdings, Inc., and NantHealth, Inc. 10-K 001-37792 2.1 February 28, 2020 10.19 Open NMS Assignment Agreement, dated as of July 22, 2020, between the Registrant and Cambridge Equities, LP. 10-Q 001-37792 10.1 August 7, 2020 10.20 Amended and Restated Promissory Note by and between the Company and Nant Capital, LLC dated as of December 31, 2020. 8-K 001-37792 10.1 January 5, 2021 10.21 Form of Exchange Agreement by and between the Company and certain holders, dated as of April 13, 2021 8-K 001-37792 10.1 April 14, 2021 10.22 Form of Exchange Agreement by and between the Company and Cambridge Equities, L.P., dated as of April 13, 2021 8-K 001-37792 10.2 April 14, 2021 10.23 Note Purchase Agreement by and among the Company, NaviNet, Inc., and certain buyers, dated as of April 13, 2021 8-K 001-37792 10.3 April 14, 2021 10.24 Third Amended and Restated Promissory Note, dated April 27, 2021, by and between NantHealth, Inc. and Nant Capital LLC 8-K 001-37792 10.1 April 28, 2021 10.25 Second Amended and Restated Promissory Note, dated April 27, 2021, by and between NantHealth, Inc. and Nant Capital LLC 8-K 001-37792 10.2 April 28, 2021 10.26 Open Market Sale AgreementSMdated November 12, 2021, by and between NantHealth, Inc. and Jefferies LLC 8-K 001-37792 10.1 November 12, 2021 21.1 Subsidiaries X 23.1 Consent of Ernst & Young LLP X 24.1 Power of Attorney (Contained on Signature Page to this Annual Report on Form 10-K). X 31.1 Certification of Principal Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1 * Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 32.2 * Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101.INS** XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. X Incorporated by Reference Number Exhibit Title Form File No. Exhibit Filing Filed Date Herewith - 144 -
RkJQdWJsaXNoZXIy NTIzOTM0